Lecanemab is a new drug that’s being made available in Canada to slow the early stage of Alzheimer’s disease. We speak to Linda McMaster, who is on the waitlist to receive it. And Drs Sandra Cohen and Samir Sinha about the efficacy, cost and reality of how this new drug fits in with the wider Alzheimer’s care environment in Canada today.
